Oncologist

Article	Citations
37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcino	78
18 Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model	76
55 Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma	75
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer	70
Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary	69
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs	62
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study	56
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy	55
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)	54
Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland	53
Classification of NK-large granular lymphocytic leukemia by CD56 expression	52
Correction to: Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)	51
Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy	47
46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)	44
Calls to action on lung cancer management and research	43
IUC24430-78 Lesion-level meta-diagnostic of cognitive vs fusion MRI-targeted biopsy in PCa: PRECISION-2 insights	43
IUC23530-78 Diagnostic value, safety, and patient-reported outcomes of total free-hand LATP biopsy technique	43
9Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)	43
56 Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer	39
Patients’ and caregivers’ perspectives on preparedness for and experience with chimeric antigen receptor T-cell therapy	39
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer	39
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer	39
IUC24025-78 Early results of moderate hypofractionated radiotherapy implementation for localized prostate cancer patients in Vietnam	39
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis	38
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience	38

Contextualizing results of randomized trials in smoldering myeloma	37
Cost implications of early treatment discontinuation in cancer: a real-world data analysis	37
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis	37
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results	36
Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience	36
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles	35
Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities	35
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay	34
Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes	34
Determining the Cancer Center priorities at the Wilmot Cancer Institute: A proposed framework informed by an academic-community collaborative approach	34
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events	34
Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review	33
The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer	33
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial	33
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation	33
Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites	33
Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate	33
Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks	32
A blueprint for creating an early-onset colorectal cancer program based on experiences from seven clinical centers across the United States and Canada	32
ALK-positive adult histiocytosis with a TFG-ALKfusion gene	32
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer	32
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma	31
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis	31
Large language model processing capabilities of ChatGPT 4.0 to generate molecular tumor board recommendations—a critical evaluation on real world data	31
Antibody drugs conjugates in non–small cell lung cancer: current status and challenges	31
First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity	30
First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors	30
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study	29
74 Unraveling the Complexities of Obesity in Clear Cell Renal Cell Carcinoma Carcinogenesis	29
Palliative Care Interventions and End-of-Life Care for Patients with Metastatic Breast Cancer: A Multicentre Analysis	29
Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy	29
Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings	28
It is time to rethink randomized clinical trial approaches	28
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer	28
Prevalence and associated factors of persistent precancerous lesions among women treated for cervical lesions in Addis Ababa, Ethiopia	27
Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries	27
Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer	27
Characteristics and availability of medicine early access programs and donations in Slovenia	27
Deep Learning of Multimodal Ultrasound: Stratifying the Response to Neoadjuvant Chemotherapy in Breast Cancer Before Treatment	27
IUC24411-77 In search of metastasis-initiating cells in prostate cancer	26
Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study	26
Response to intra-arterial chemotherapy in patients with adenoid cystic carcinoma of lacrimal gland	26
IUC24420-77 Prognostic impact of ABCA1/ABCG1 expression, lipid parameters, and nephrectomy in patients with renal cell carcinoma receiving immune checkpoint inhibitors	26
Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board	26
Understanding variants of unknown significance and classification of genomic alterations	25
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma	25
Oncofusions – shaping cancer care	25
35FGD1 splice variant as a novel biomarker for inferior clinical outcomes and development of brain and bone metastasis in clear cell renal cell carcinoma	25
A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment	25
4CD163+ Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial	25

Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness	25
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy	24
Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan	24
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC	23
Adherence to oral antineoplastic agents, an overview and meta-analysis	23
Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget’s disease	23
Melanoma of unknown primary: a comprehensive review of immune-mediated pathogenesis and therapies	22
25 Enrichment of tertiary lymphoid structures provides novel insight into mediators of anti-tumor immune activity in sarcomatoid renal cell carcinoma	22
How often do oncologists receive industry payments from competing companies?	22
Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis	22
Primary brainstem lymphoma: clinical characteristics, treatment methods, and prognostic factors of 56 patients	22
An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma	22
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research	22
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma	22
Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of life	22
Assessing the clinical readiness of the SERENA-6 strategy	22
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors	22
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials	22
Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy	22
The cervical cancer screening and precancer treatment journey: a qualitative study of experiences among Zambian women living with and without HIV	22
IUC24394-87 Meet-URO score update in metastatic renal cell carcinoma receiving first-line immune-combinations	21
Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients	21
IUC23223-77 Triplet therapy in metastatic hormone-sensitive prostate cancer in Asian patients	21
IUC24392-85 Real-world use of erdafitinib in urothelial carcinoma: an Italian multicenter retrospective study	21
“Our Community is not Appropriately Served”: LGBTQ+ Cancer Survivors and Caregivers have Suggestions for Providers	21
IUC24405-80 Retrospective study of apalutamide/enzalutamide in hormone-sensitive metastatic prostate cancer	21
EMBARK in biochemically recurrent prostate cancer: a journey for some but not most	21
Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?	21
Proceedings of the 1st biannual bridging the gaps in lung cancer conference	20
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399	20
7Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)	20
Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm	20
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review	20
50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study	20
Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors	20
Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram	20
33fusion derived oncogenic programs shape the immune landscape in translocation renal cell carcinoma	20
Malnutrition in gastrointestinal cancer manifests before systemic therapy and is associated with fatigue and reduced physical quality of life	19
Advances in the management of patients with IDH-mutant glioma	19
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study	19
Prevalence and spectrum of homologous recombination repair mutations in patients with metastatic prostate cancer from India	19
Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity	19
68Targeting the BBOX1-TBK1-mTORC1 axis in clear cell renal cell carcinoma	19
Clinical and radiomics parameter prognostication in metastatic uveal melanoma patients treated with hepatic arterial infusion chemotherapy	19
Opioid use and adverse health effects in breast cancer survivors	19
Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis	19
Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series	19
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States	19
Care coordination and communication for Native American patients with cancer	19
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study	18
Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma	18
Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?	18
Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression	18
Ovarian clear cell carcinoma: open questions on the management and treatment algorithm	18
58Dissecting the interplay between Bap1 and Pbrm1 in renal cell carcinoma	18
Chatbot assistance in precision oncology treatment decision-making	18
Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study	18
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma	18
Machine learning models for predicting postoperative peritoneal metastasis after hepatocellular carcinoma rupture: a multicenter cohort study in China	18
KRASMutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas	18
Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities	18
The association of health care contact days with economic measures in the CCTG LY.12 trial	18
Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer	18
Clinical response to novel combination of trastuzumab deruxtecan and abiraterone in HER2-expressing metastatic castration-resistant prostate cancer	18
Correction to: Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake	17
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments	17
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast	17
Implementation of Precision Oncology in Clinical Practice: Results of a National Survey for Health Care Professionals	17
Immune-related encephalitis after immune checkpoint inhibitor therapy	17
Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis	17
Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice	17
A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH)	17
STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC	17
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study	17
Medical accuracy of artificial intelligence chatbots in oncology: a scoping review	17
HER2 alterations across solid tumors: implications for comprehensive testing	17
Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia	17
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients	17
IUC24412-78 The safety and efficacy of a modified Di stasi regime for patients with non-muscle invasive bladder cancer during times of bacillus Calmette-Guérin shortage	17
The utility of ctDNA in rectal cancer	17

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53	17
Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?	16
Outcomes of palliative porto-mesenteric venous stenting in unresectable pancreatic malignancies	16
Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles	16
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer	16
Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies	16
An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer	16
Advanced ampullary cancer: post-hoc analysis of the ABC-01, ABC-02, and ABC-03 clinical trials	16
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan	16
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors	16
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma	16
Real-world effectiveness and safety of hyperthermic intraperitoneal chemotherapy and intraperitoneal chemotherapy in ovarian cancer	16
Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors	16
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study	15
COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review	15
A phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: first clinical agent targeting APE1/Ref-1 in cancer	15
Clinical outcomes in older adults with advanced thyroid cancer	15
Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program	15
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab	15
PEComas: Current Concepts in Diagnosis, Molecular Pathways, and Emerging Treatments	15
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial	15
ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations	15
First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer	15
Emerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review	15
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma	15
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study	15
Accuracy of patient, care partner, and clinician health care contact day recall	15
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors	15
Symptom Clusters in Patients With Advanced Cancer: A Prospective Longitudinal Cohort Study to Examine Their Stability and Prognostic Significance	15
Stigma and Social Determinants of Health Associated With Fidelity to Guideline-Concordant Therapy in Patients With Breast Cancer Living With and Without HIV in Botswana	15
The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms	15
Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations	15
A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX	15
Correction to: Comparing Drug Shortages Experienced by Institutions With National Metrics	14
The albumin–bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy	14
18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis	14
A Lung Cancer Patient’s Passionate Desire for Sexual Healing	14
54 MicroRNA Signatures in Clear Cell Renal Cell Carcinoma: Exploring Potential Implications for Prognosis	14
Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic	14
IUC24428-85 Real-world effectiveness of ipilimumab plus nivolumab in second-line in patients with metastatic clear cell renal cell carcinoma (mccRCC) based on prior receipt of PD-1/L1 inhibitors	14
Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial	14
Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma	14
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel	14
Multidisciplinary team diagnosis and treatment of well-differentiated thyroid carcinoma: current landscape and future prospects	14
Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors	14
Intravenous haloperidol or chlorpromazine—which is more effective to improve agitation and communication in agitated delirium at the end of life?	14
Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades	14
Adjuvant treatment preferences in high-risk upper tract urothelial carcinoma: the perspective of Portuguese medical oncologists	14
Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK	14
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis	14
Advances and future directions in ROS1 fusion-positive lung cancer	14
Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors	14
Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review	14
Correction to: A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study	14
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan	14
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study	14
The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice	14
IUC24409-84 Evaluation of a transurethral laser ablation (TULA) service for superficial bladder cancer management in an outpatient setting in a UK district general hospital	14
A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy	13
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab	13
Trends, Changes, and Disruptions: The Fragile Economics of Cancer Treatments	13
Association between pathologic chemotherapy response score and pattern of recurrence in advanced high-grade serous ovarian cancer	13
Prognostic and histologic significances of the expression profile of membrane tissue factor for aggressive endometrial carcinomas	13
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors	13
Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study	13
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia	13
Validation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer	13
Fanconi anemia complementation group C gene (FANCC) association with hereditary and sporadic renal tumors	13
Questioning the association between prophylactic antibiotics and improved prognosis in gastric cancer immunotherapy	13
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial	13
Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies	13
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center	13
Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials	13
Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE	13
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses	13
Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview	13
The cancer caregiving burden trajectory over time: varying experiences of perceived versus objectively measured burden	13
Availability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 Years	13
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101	13
Phase II study of maintenance trifluridine/tipiracil (TAS-102) plus bevacizumab after induction chemotherapy in metastatic colorectal cancer	13
Impact of geriatric covariates on metronomic cyclophosphamide efficacy and tolerance—the CHEMETROLD study	13
Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR	12
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma	12
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation	12
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study	12
Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer	12
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer	12
Home-based supervised exercise on metastatic cancer patients receiving oral targeted therapy: the AFSOS-Unicancer QUALIOR randomized phase 2 study	12
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes	12
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer	12
Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine	12
Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations	12
Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis	12
Pregnancy-associated cancer death in the United States, 2018-2023	12
Moving the Pendulum for Glioblastoma Treatment: One Injection at a Time	12